Developer docs
API playgroundTry for free, no card

Search company profiles

Sorintellis

Full company profile

uuid002jzzn

Namestring
Sorintellis
Legal namestring
Sorintellis Group Inc
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Sorintellis Group Inc is a Montreal-based, privately held AI software company founded in 2022 that builds clinical drug development intelligence infrastructure for the pharmaceutical industry. The company's product is centered on TrialsBank™, a proprietary, deeply curated clinical development data foundation integrating multi-dimensional data across scientific, clinical, operational, regulatory, and financial domains, and trained on hundreds of thousands of curated clinical trials. On top of TrialsBank™, Sorintellis sells two AI-powered solutions — D.O.P.E. for Clinical Trials (covering Design, Optimize, Prioritize, and Execute phases) and D.O.P.E. for Pharmaceutical Portfolio Management (enabling scenario simulation and dynamic optimization across assets, indications, and development pathways) — combining predictive and causal AI to support trial design, risk prediction, resource allocation, and portfolio strategy decisions.

The company serves three primary customer segments: pharmaceutical companies (with Pfizer as a named collaboration partner), life sciences investment funds seeking asset valuation and portfolio management, and contract research organizations (CROs) executing clinical trials. Sorintellis operates an enterprise-focused direct sales motion with a "Request a demo" funnel and quote-based pricing; pricing is not publicly disclosed and no published revenue, ARR, or funding rounds are on record. The company has built a dense ecosystem of strategic collaborators, including Université de Montréal, Université Laval, Polytechnique Montréal, Mila (Quebec AI Institute), IVADO, HEC Montréal, Vantage Biotrials, CQDM, MITACS, Pfizer, BioQuebec, and Amorchem, which provide research validation, talent pipelines, and grant/co-development funding. Recognition includes finalist status in the ADRIQ Prix Innovation 2025 and inclusion in HackerNoon's global winning startup list.

Short descriptiontext

Sorintellis is a Montreal-based AI software company that builds TrialsBank™, a proprietary clinical development data foundation, and sells D.O.P.E. AI solutions to pharmaceutical companies, life sciences investment funds, and CROs for clinical trial design, risk prediction, and portfolio management.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMontreal, Canada
HQ citystring
Montreal
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical trial intelligence, pharmaceutical portfolio management, AI drug development, clinical risk prediction, pharma R&D analytics
Industry2 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Computer Systems Design Services541512
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Prepackaged Software7372
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical Trial Intelligence / Pharmaceutical R&D Analytics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1AI Platform/SaaS Subscription
TypeSubscription Recurring
Description

Likely subscription-based access to TrialsBank™ platform and D.O.P.E. solutions for pharmaceutical portfolio management and clinical trial intelligence.

sorintellisgroup.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1TrialsBank™
Description

A deeply curated and validated clinical development data foundation that integrates multi-dimensional data across scientific, clinical, operational, regulatory, and financial domains to enable advanced AI applications for clinical development.

sorintellisgroup.com
Core offering1 text field

Sorintellis provides an AI-powered clinical development intelligence platform anchored by its proprietary TrialsBank™ data foundation, which integrates multi-dimensional data across scientific, clinical, operational, regulatory, and financial domains. The platform delivers two solutions under the D.O.P.E. methodology (Design, Optimize, Prioritize, Execute): one for clinical trial intelligence and one for pharmaceutical portfolio management, enabling optimized protocol design, risk prediction, asset valuation, and portfolio strategy simulation for pharmaceutical companies, life sciences investment funds, and CROs.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Sorintellis offers a unified platform architecture centered on TrialsBank™ as the core data intelligence infrastructure, with two primary AI-powered solutions built upon it: D.O.P.E. for Clinical Trials and D.O.P.E. for Pharmaceutical Portfolio Management. TrialsBank™ provides the curated clinical development data foundation that powers both solutions, enabling AI-driven applications across trial design, execution, risk prediction, asset valuation, and portfolio optimization.

Product and service3 records
1TrialsBank™
CategoryCore Data Platform
Description

Proprietary, deeply curated and validated clinical development data foundation that integrates multi-dimensional data across scientific, clinical, operational, regulatory, and financial domains; serves as the structured intelligence layer powering all Sorintellis AI applications. Built and validated over years, providing the context required to uncover true drivers of trial outcomes beyond what is available in public databases. Aimed at pharmaceutical companies, life sciences investment funds, and CROs.

2D.O.P.E. for Clinical Trials
3D.O.P.E. for Pharmaceutical Portfolio Management
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership18 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-07
Description

Academic partnership in strategic scientific collaboration to advance TrialsBank™-powered clinical trial intelligence. Contributes academic expertise from leading Quebec research institution.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-07
Description

Academic partner in strategic collaboration developing AI-driven recommendation engines for clinical trial decision-making, portfolio strategy, and valuation.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-07
Description

AI research institute partnership for developing recommendation engines to optimize clinical development across trial design, operational execution, and portfolio strategy.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-07
Description

Strategic scientific collaboration with IVADO (Institute for Data-Driven Value Creation) to advance clinical trial intelligence layer powered by TrialsBank™.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-07
Description

Clinical trial execution expertise partner joining AI collaboration to advance clinical trial intelligence and improve trial execution with TrialsBank™.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-24
Description

Partnership to transform pharmaceutical portfolio management through AI with MITACS support. Decision-making system development for strategic portfolio management.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration to develop AI-based platform aimed at efficiently mitigating risks in clinical drug development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-funding development of AI-powered platform to mitigate clinical trial risks, including funding for research and development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic research partnership supporting AI training and development of solutions for strategic pharmaceutical portfolio management based on clinical trial success estimation.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership to optimize complex decision-making processes in clinical drug development using AI and machine learning.

11Polytechnique Montréal
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partner in AI-driven pharmaceutical portfolio management transformation with MITACS support.

sorintellisgroup.com
12Prompt Innov
Strategic tierMinorTypeGTM or Marketing Partner
Description

Featured on Prompt Innov platform with CEO interview and project coverage.

sorintellisgroup.com
Strategic tierMinorTypeGTM or Marketing Partner
Description

Partner logo displayed indicating government/regional support.

14Brouillette
Strategic tierMinorTypeGTM or Marketing Partner
Description

Partner logo displayed on website.

sorintellisgroup.com
Strategic tierMinorTypeGTM or Marketing Partner
Description

Quebec biotech industry association partnership.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic partner from Quebec business school.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partner logo displayed - Quebec-based biotech investment firm.

18CTS Santé
Strategic tierMinorTypeGTM or Marketing Partner
Description

Partner logo displayed - health sector organization.

sorintellisgroup.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sorintellis

Clinical Trial Intelligence / Pharmaceutical R&D Analyticssorintellisgroup.com

Sorintellis is a Montreal-based AI software company that builds TrialsBank™, a proprietary clinical development data foundation, and sells D.O.P.E. AI solutions to pharmaceutical companies, life sciences investment funds, and CROs for clinical trial design, risk prediction, and portfolio management.

What Sorintellis does

Sorintellis Group Inc is a Montreal-based, privately held AI software company founded in 2022 that builds clinical drug development intelligence infrastructure for the pharmaceutical industry. The company's product is centered on TrialsBank™, a proprietary, deeply curated clinical development data foundation integrating multi-dimensional data across scientific, clinical, operational, regulatory, and financial domains, and trained on hundreds of thousands of curated clinical trials. On top of TrialsBank™, Sorintellis sells two AI-powered solutions — D.O.P.E. for Clinical Trials (covering Design, Optimize, Prioritize, and Execute phases) and D.O.P.E. for Pharmaceutical Portfolio Management (enabling scenario simulation and dynamic optimization across assets, indications, and development pathways) — combining predictive and causal AI to support trial design, risk prediction, resource allocation, and portfolio strategy decisions.

The company serves three primary customer segments: pharmaceutical companies (with Pfizer as a named collaboration partner), life sciences investment funds seeking asset valuation and portfolio management, and contract research organizations (CROs) executing clinical trials. Sorintellis operates an enterprise-focused direct sales motion with a "Request a demo" funnel and quote-based pricing; pricing is not publicly disclosed and no published revenue, ARR, or funding rounds are on record. The company has built a dense ecosystem of strategic collaborators, including Université de Montréal, Université Laval, Polytechnique Montréal, Mila (Quebec AI Institute), IVADO, HEC Montréal, Vantage Biotrials, CQDM, MITACS, Pfizer, BioQuebec, and Amorchem, which provide research validation, talent pipelines, and grant/co-development funding. Recognition includes finalist status in the ADRIQ Prix Innovation 2025 and inclusion in HackerNoon's global winning startup list.

Sorintellis firmographics

Firmographics
Name
Sorintellis
Legal name
Sorintellis Group Inc
Website
https://sorintellisgroup.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
1–10 employees
Short description
Sorintellis is a Montreal-based AI software company that builds TrialsBank™, a proprietary clinical development data foundation, and sells D.O.P.E. AI solutions to pharmaceutical companies, life sciences investment funds, and CROs for clinical trial design, risk prediction, and portfolio management.
Ownership category
akta.pro rank

Sorintellis industry classification

Industry
Product category
Clinical Trial Intelligence / Pharmaceutical R&D Analytics
NAICS
Computer Systems Design Services (541512), Scientific Research and Development Services (5417)
SIC
Services-Prepackaged Software (7372), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Clinical trial intelligence
  • Pharmaceutical portfolio management
  • AI drug development
  • Clinical risk prediction
  • Pharma R&D analytics

Where Sorintellis is headquartered

Location

Headquarters

HQ city
Montreal
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Sorintellis business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. AI Platform/SaaS Subscription: Likely subscription-based access to TrialsBank™ platform and D.O.P.E. solutions for pharmaceutical portfolio management and clinical trial intelligence.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Sorintellis product offering

Product offering

Core offering

Sorintellis provides an AI-powered clinical development intelligence platform anchored by its proprietary TrialsBank™ data foundation, which integrates multi-dimensional data across scientific, clinical, operational, regulatory, and financial domains. The platform delivers two solutions under the D.O.P.E. methodology (Design, Optimize, Prioritize, Execute): one for clinical trial intelligence and one for pharmaceutical portfolio management, enabling optimized protocol design, risk prediction, asset valuation, and portfolio strategy simulation for pharmaceutical companies, life sciences investment funds, and CROs.

Product overview

Sorintellis offers a unified platform architecture centered on TrialsBank™ as the core data intelligence infrastructure, with two primary AI-powered solutions built upon it: D.O.P.E. for Clinical Trials and D.O.P.E. for Pharmaceutical Portfolio Management. TrialsBank™ provides the curated clinical development data foundation that powers both solutions, enabling AI-driven applications across trial design, execution, risk prediction, asset valuation, and portfolio optimization.

Differentiator

Problem solved

Functional benefit

Brands

  • TrialsBank™: A deeply curated and validated clinical development data foundation that integrates multi-dimensional data across scientific, clinical, operational, regulatory, and financial domains to enable advanced AI applications for clinical development.

Products and services

  • TrialsBank™ Proprietary, deeply curated and validated clinical development data foundation that integrates multi-dimensional data across scientific, clinical, operational, regulatory, and financial domains; serves as the structured intelligence layer powering all Sorintellis AI applications. Built and validated over years, providing the context required to uncover true drivers of trial outcomes beyond what is available in public databases. Aimed at pharmaceutical companies, life sciences investment funds, and CROs.
  • D.O.P.E. for Clinical Trials
  • D.O.P.E. for Pharmaceutical Portfolio Management

Companies that use Sorintellis

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Sorintellis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Sorintellis partnerships and signals

Strategic signal

Partnerships

18 partnerships are on record, tiered core and minor.

  • Université de MontréalcoreStrategic or Co-development Partner · 7 April 2026Academic partnership in strategic scientific collaboration to advance TrialsBank™-powered clinical trial intelligence. Contributes academic expertise from leading Quebec research institution.
  • Université LavalcoreStrategic or Co-development Partner · 7 April 2026Academic partner in strategic collaboration developing AI-driven recommendation engines for clinical trial decision-making, portfolio strategy, and valuation.
  • Mila - Quebec Artificial Intelligence InstitutecoreStrategic or Co-development Partner · 7 April 2026AI research institute partnership for developing recommendation engines to optimize clinical development across trial design, operational execution, and portfolio strategy.
  • IVADOcoreStrategic or Co-development Partner · 7 April 2026Strategic scientific collaboration with IVADO (Institute for Data-Driven Value Creation) to advance clinical trial intelligence layer powered by TrialsBank™.
  • Vantage BiotrialscoreStrategic or Co-development Partner · 7 April 2026Clinical trial execution expertise partner joining AI collaboration to advance clinical trial intelligence and improve trial execution with TrialsBank™.
  • IVADO, Polytechnique Montréal, Université de MontréalcoreStrategic or Co-development Partner · 24 May 2024Partnership to transform pharmaceutical portfolio management through AI with MITACS support. Decision-making system development for strategic portfolio management.
  • PfizercoreStrategic or Co-development PartnerCollaboration to develop AI-based platform aimed at efficiently mitigating risks in clinical drug development.
  • CQDMcoreStrategic or Co-development PartnerCo-funding development of AI-powered platform to mitigate clinical trial risks, including funding for research and development.
  • MITACScoreStrategic or Co-development PartnerAcademic research partnership supporting AI training and development of solutions for strategic pharmaceutical portfolio management based on clinical trial success estimation.
  • MilacoreStrategic or Co-development PartnerPartnership to optimize complex decision-making processes in clinical drug development using AI and machine learning.
  • Polytechnique MontréalcoreStrategic or Co-development PartnerAcademic partner in AI-driven pharmaceutical portfolio management transformation with MITACS support.
  • Prompt InnovminorGTM or Marketing PartnerFeatured on Prompt Innov platform with CEO interview and project coverage.
  • Quebec Ministry of EconomyminorGTM or Marketing PartnerPartner logo displayed indicating government/regional support.
  • BrouilletteminorGTM or Marketing PartnerPartner logo displayed on website.
  • BioQuebecminorGTM or Marketing PartnerQuebec biotech industry association partnership.
  • HEC MontréalminorStrategic or Co-development PartnerAcademic partner from Quebec business school.
  • AmorchemminorStrategic or Co-development PartnerPartner logo displayed - Quebec-based biotech investment firm.
  • CTS SantéminorGTM or Marketing PartnerPartner logo displayed - health sector organization.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Sorintellis competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key highlights7 records

Customer concentration

Sorintellis social profiles

Digital presence

Sorintellis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sorintellis leadership team

Management profile

Number of profiles

Profiles2 records

Sorintellis funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sorintellis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sorintellis

What does Sorintellis do?

Sorintellis provides an AI-powered clinical development intelligence platform anchored by its proprietary TrialsBank™ data foundation, which integrates multi-dimensional data across scientific, clinical, operational, regulatory, and financial domains. The platform delivers two solutions under the D.O.P.E. methodology (Design, Optimize, Prioritize, Execute): one for clinical trial intelligence and one for pharmaceutical portfolio management, enabling optimized protocol design, risk prediction, asset valuation, and portfolio strategy simulation for pharmaceutical companies, life sciences investment funds, and CROs.

Is Sorintellis a public or private company?

Sorintellis is a private company. It is classified as unknown and is currently operating.

When was Sorintellis founded?

Sorintellis was founded in 2022. It employs 1 to 10 people.

Where is Sorintellis based?

Sorintellis is headquartered in Montreal, Canada, in the North America region.

How does Sorintellis make money?

One revenue line is on record: AI Platform/SaaS Subscription.

Does Sorintellis have an API?

No public API is recorded for Sorintellis.

What industry is Sorintellis in?

Sorintellis's product category is Clinical Trial Intelligence / Pharmaceutical R&D Analytics. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution). Its NAICS code is 541512 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
HecHEC Montréal Partner with Sorintellis to Advance AI-Powered Drug Asset Valuation and Decision IntelligenceSorintellis announced a collaboration with HEC Montréal and IVADO to develop an AI-based drug asset valuation framework using its TrialsBank™ data. The project integrates machine learning risk predictions into sequential financial decision models for pharmaceutical R&D. The framework is expected to support capital allocation, licensing, and portfolio optimization decisions.NewswireDecision Sciences and Finance Researchers at HEC Montréal Partner with Sorintellis to Advance AI-Powered Drug Asset Valuation and Decision Intelligence Through TrialsBank™Sorintellis and HEC Montréal announced a collaboration to develop AI-based drug asset valuation using its TrialsBank data infrastructure. The project integrates machine learning risk predictions with sequential financial decision models for pharmaceutical asset valuation. The framework is expected to support capital allocation, licensing, partnering, and portfolio optimization decisions.HecDecision Sciences and Finance Researchers at HEC Montréal Partner with Sorintellis to Advance AI-Powered Drug Asset Valuation and Decision Intelligence Through TrialsBank™Sorintellis announced a strategic collaboration with HEC Montréal researchers in decision sciences and finance, supported by IVADO and Mitacs, to advance AI-powered drug asset valuation using its proprietary TrialsBank™ dataset. The initiative aims to develop a framework integrating machine learning-derived risk predictions with dynamic financial decision models to support capital allocation, licensing, partnering, and portfolio optimization across biotechnology and pharmaceutical organizations. This collaboration is positioned as a structural enhancement to clinical development investment risk assessment, leveraging Quebec's AI ecosystem and academic expertise.NewswireSorintellis, Vantage Biotrials, Université de Montréal, Université Laval and IVADO Announce Strategic Scientific Collaboration to Advance a Clinical Trial Intelligence Layer Powered by TrialsBank™Sorintellis announced a strategic scientific collaboration with academic experts from Université de Montréal, Université Laval, Mila – Quebec Artificial Intelligence Institute, and IVADO to advance its TrialsBank™-powered intelligence infrastructure for clinical trial decision-making. The initiative focuses on developing AI-driven recommendation engines to optimize clinical development across trial design, operational execution, portfolio strategy, valuation, and high-stakes decision-making. The collaboration draws on multiple industry-supported pilot projects leveraging a curated clinical development dataset, representing what Sorintellis describes as a structural shift toward data-driven clinical development infrastructure.